My Cart

Integrin alpha L beta 2

Integrin alpha L beta 2 Overview

English NameIntegrin alpha-L/beta-2 (LFA-1)Approved Drugs1
Drugs in Clinical Trials1Target SynonymLymphocyte Function-Associated Antigen-1
Highest Development StageApproved
English NameIntegrin alpha-L/beta-2 (LFA-1)
Target SynonymLymphocyte Function-Associated Antigen-1
Approved Drugs1
Drugs in Clinical Trials1
Highest Development StageApproved

Integrin alpha L beta 2 Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeatureOrder Now
IT2-H53W3
Human
CHO
Human Integrin alpha L beta 2 (ITGAL&ITGB2) Heterodimer Protein, His Tag&Tag Free
Add to Cart
Total: 1
  • 1

Integrin alpha L beta 2 Background

Integrin alpha-L beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin alpha L beta 2 is also a receptor for F11R (By similarity). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Required for generation of common lymphoid progenitor cells in bone marrow, indicating the role in lymphopoiesis. Integrin alpha L beta 2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages.

Integrin alpha L beta 2 Synonyms

Integrin alpha L beta 2,ITGAL&ITGB2

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Alintegimod7HP349; 7-HP-349; 7HP-349Phase 2 Clinical7 Hills Pharma LLCCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
LifitegrastSHP-606; SAR-1119; SAR-1118; SPD-606; OJL-332ApprovedShire Development LlcXiidra, 朗悦明United StatesDry Eye SyndromesBausch And Lomb Inc2016-07-11Conjunctivitis, Allergic; Diabetic macular oedema; Dry Eye Syndromes; Graft vs Host Disease; Keratoconjunctivitis Sicca; Xerophthalmia
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland